ACIU vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ACIU's Advanced Deterministic Scorecard reveals severe financial distress: a Piotroski F-Score of 1/9 indicates extreme weakness in operational and financial health, while the absence of an Altman Z-Score raises unquantified bankruptcy risk. Despite a strong analyst consensus of 'strong_buy' and a target price of $8.98, the company exhibits catastrophic profitability metrics—negative ROE (-74.63%), gross and net margins at 0%, and a staggering -1671.88% operating margin. Revenue has collapsed by 96.3% YoY, and the stock trades at an absurd Price/Sales of 69.38, far exceeding peer benchmarks. The 52-week range ($1.43–$4.00) and 5-year decline of 62.7% underscore long-term underperformance, despite recent short-term price gains.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ACIU vs LLY: Head-to-Head Comparison
This page compares AC Immune SA (ACIU) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.